Two new treatments for Crohn's disease equally effective
Two new treatments for Crohn's disease showed roughly equal performance in a clinical trial, according to findings published in The Lancet.
Jul 18, 2022
1
78
Two new treatments for Crohn's disease showed roughly equal performance in a clinical trial, according to findings published in The Lancet.
Jul 18, 2022
1
78
Chronic or acute inflammation can contribute to a range of ailments—some potentially deadly—including stroke, respiratory and heart disease, cancer, arthritis, asthma, dementia, multiple sclerosis, and diabetes. In May, ...
Jul 12, 2022
0
48
Scientists from St. Jude Children's Research Hospital have shown that the innate immune sensor, ZBP1, and its associated inflammatory cell death pathway, PANoptosis, are major contributors to the negative effects of interferon ...
May 19, 2022
0
39
Brain fog, headaches, and insomnia are some of the neurological symptoms doctors have observed in COVID-19 patients. Neurological sequelae after a viral infection is not new—in fact, following the 1918 influenza pandemic, ...
May 18, 2022
0
120
Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe ...
May 17, 2022
0
34
Yale researchers have identified a particular immune response pathway that leads to severe illness and death in people infected by the SARS-CoV-2 virus.
Apr 28, 2022
0
55
New research results demonstrate how inflammation from a COVID-19 infection during pregnancy could potentially impact long-term infant health, including infant growth and brain development. Published in the Journal of Perinatology, ...
Apr 25, 2022
0
61
New research being presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April) has identified a panel of cytokines that can help predict which COVID-19 ...
Apr 23, 2022
0
24
A UCLA-led team of researchers studying the effect of the monoclonal antibody Leronlimab on long COVID-19 may have found a surprising clue to the baffling syndrome, one that contradicts their initial hypothesis. An abnormally ...
Apr 22, 2022
1
675
Axicabtagene ciloleucel (axi-cel; Yescarta) was approved for treatment of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy, the U.S. Food ...
Apr 15, 2022
0
3